英国儿童季节性鼻喷流感疫苗(Fluenz® Tetra)加强被动安全监测:八个流感季的方法、结果与经验
本文介绍2015/2016至2022/2023八个流感季在英国英格兰地区对2-17岁儿童接种Fluenz® Tetra鼻喷流感疫苗实施的加强被动安全监测(EPSS)。采用前瞻性非干预设计,通过安全报告卡收集不良药物反应报告并估算风险,结果显示各季报告率低、严重ADR罕见,支持该疫苗在儿童中的正向获益-风险特征。
要点
- EPSS采用前瞻性非干预设计,通过安全报告卡加强自发报告并获取分母数据。
- 八个流感季中,每季发放8753-17,922张安全报告卡,报告返回率从1.9%降至0.4%。
- 鼻漏是最常报告的不良反应(0.1%-0.6%),严重ADR罕见。
核心结论
- EPSS作为常规药物警戒的有价值延伸,促进了近实时患者报告结局收集及风险估算的分母数据获取。
- 八个流感季报告的ADR频率均较低,尽管可能存在一定程度的漏报,结果支持Fluenz® Tetra在儿童中的正向获益-风险特征。
研究设计与样本
- 前瞻性、非干预性设计,加强不良药物反应(ADR)的自发报告。
- 在2015/2016至2022/2023八个流感季,由全科诊所/学校免疫团队在接种后向接种者或其代表发放安全报告卡(SRC),仅当发生ADR时要求返回。
- 每个流感季有38-49家全科诊所和25-50所学校参与,每年发放8753-17,922张SRC,发放数量作为风险估算的分母。
- 采用描述性分析。
主要发现
- 合格SRC的返回率在2015/2016季最高为1.9%,至2022/2023季降至0.4%。
- 所有流感季中,大多数报告来自2-4岁儿童(41.3%-64.4%)。
- 鼻漏在所有流感季中最常被报告(0.1%-0.6%)。
- 严重ADR罕见。
临床怎么用
- EPSS方法可近实时收集患者报告的不良反应及分母数据,用于风险估算。
- 监测结果显示儿童接种Fluenz® Tetra后ADR报告频率低,严重ADR罕见,支持其获益-风险特征。
局限性
- 尽管采用加强方法,仍可能存在一定程度的漏报。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
INTRODUCTION: Fluenz® Tetra, an intranasal influenza vaccine, was recommended for children aged 2-17 years as part of the UK influenza vaccination campaign. Following regulatory guidance issued by the European Medicines Agency (EMA), enhanced passive safety surveillance (EPSS) was conducted annually for Fluenz® Tetra to monitor its safety in real-time. OBJECTIVE: To evaluate the methodological approach implemented for EPSS of Fluenz® Tetra in England. METHODS: The EPSS used a prospective, non-interventional design to enhance spontaneous reporting of adverse drug reaction (ADRs). Over eight influenza seasons (2015/2016-2022/2023), GP practices/school immunisation teams handed out a safety report card (SRC) to vaccinees or their representatives following vaccination. Recipients were asked to return the SRC only if an ADR occurred. Sites recorded the number of SRCs distributed, which served as the denominator for risk estimates. Descriptive analyses were performed. RESULTS: Each season, between 38 and 49 GP practices and 25-50 schools participated. A total of 8753-17,922 SRCs were issued annually. Return rates for eligible SRCs were highest in 2015/2016 (1.9%), declining to 0.4% in 2022/2023. In all seasons, most reports received were for 2-4-year-olds (41.3%-64.4%). Rhinorrhoea was most frequently reported across all seasons (0.1%-0.6%). Serious ADRs were rare. CONCLUSIONS: The EPSS served as a valuable extension to routine pharmacovigilance, by facilitating near real-time collection of patient-reported outcomes, alongside denominator data for risk estimates. ADR frequencies reported across seasons were low. Whilst some degree of underreporting may have remained despite the enhanced methodology, findings supported the positive benefit-risk profile of Fluenz® Tetra in children over eight seasons.
引用
- Dhanda S, Morris DE, Morton K, et al. Enhanced passive safety surveillance (EPSS) of a seasonal intranasal influenza vaccine (Fluenz® Tetra) in children in England: methodology, results and lessons learned from eight influenza seasons (2015/2016 to 2022/2023). Vaccine. 2026. PMID: 42607627. doi:10.1016/j.vaccine.2026.129007
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。